Bonnie H. Anderson
Bonnie H. Anderson is Chairman and Chief Executive Officer of Veracyte, a leading genomic diagnostics company that improves the lives of patients by reducing diagnostic uncertainty in healthcare – enabling patients to get clearer answers and avoid invasive surgeries and other costly procedures. Her career spans over 30 years in regulated diagnostics and life science markets. Ms. Anderson cofounded Veracyte in 2008 and served as the company’s President and Chief Executive Officer until 2016, when she was also appointed Chairman of the Board. She took the company public in 2013 and spearheaded commercialization of Veracyte’s first three market-leading products. Veracyte’s genomic tests are setting new standards in thyroid and lung cancer diagnosis, where they have helped tens of thousands of patients avoid unnecessary surgery.
Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the board of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana University of Pennsylvania with a Bachelor of Science degree in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. In 2017, Ms. Anderson received the prestigious Wallace H. Coulter Award for Healthcare Innovation and was also named one of FiercePharma’s “Fiercest Women in Life Sciences.” In 2015, Fast Company magazine featured Ms. Anderson on its “100 Most Creative People in Business” list. She was named one of the “Most Influential Women in Bay Area Business” (2013) and one of the “Bay Area’s Most Admired CEOs” (2014) by the San Francisco Business Times, and has also received the Silicon Valley Business Journal’s “Women of Influence” award (2013).